Abstract:Aims & Objectives: Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the landscape of cancer therapy, obtaining significant efficacy especially in relapsed and refractory (R/R) B cell malignancies. In clinical patients, CAR-T cells are able to migrate into various organs and exert cytotoxicity on tumor cells, including the central nervous system (CNS), which serves as an immunological privileged site protected from peripheral blood. However, whether there is a possibility of the CNS relapse in patients with B-cell lymphoma who achieved complete remission (CR) after CAR-T cell therapy has not been reported yet. We aim to describe the features of the CNS relapse after CAR-T cell therapy in B-cell lymphoma, and try to identify correlated factors and propose potential management strategy in the upcoming research. Patients/Materials & Methods: We preliminarily reviewed 12 patients (5 presented) who received CAR-T cell therapy for the treatment B-cell lymphoma in our center and Shenzhen University General Hospital. We compared the baseline of patient characteristics before CAR-T cell therapy, described the clinical response and efficacy during the treatment, and reported the occurrence of CNS relapse after achieving CR. Results: All 5 patients were heavily pre-treated with multiple lines of chemotherapy prior to CAR-T cell therapy, with 2 of them received additional autologous hematopoietic stem cell transplantation (HSCT) (Table 1). All patients suffered from previous relapse in multiple peripheral lymph nodes, with 2 of them involved in other organs like liver and breast, and 1 of them involved in the CNS. Three patients received CD19-22 bispecific CAR-T product, 1 patient received CD19-20 bispecific CAR-T product, and 1 patient received CD19 CAR-T product (Table 2). All patients responded well with tolerable toxicities by monitoring body temperature, inflammation markers, cytokines, and hemogram, and all achieved CR by PET/CT after CAR-T treatment (Figure 1). All patients eventually developed isolated CNS relapse with different locations, respectfully, which was confirmed by imaging along with pathological diagnosis or targeted drug treatment (Figure 2). Discussion & Conclusion: We first reported the CNS relapse after CAR-T cell therapy in patients with B-cell lymphoma, suggesting that routine monitory is required for patients who achieved remission after CAR-T treatment to manage the CNS involvement in time. If possible, additional application of PD-1 monoclonal antibody, BTK inhibitors or other immunomodulatory drugs that can function in the CNS might prevent the CNS relapse without affecting CAR-T cell function. Conflict of Interest Statement: No conflict of interest to disclose. Figure 1. Clinical responses and hematological toxicities during CAR-T treatment among 3 patients with CNS relapse after therapy. (A) Body temperature. (B) Levels of inflammation markers including C reactive protein (CRP), ferritin, and D-dimer. (C) Levels of cytokines, including interleukin (IL)-2, IL-6, IL-10, and interferon-γ (INF-γ). (D) Hemogram (ie. Neutrophils, lymphocytes, platelet, and hemoglobin). Figure 2. Central nervous system relapse among 3 patients after CAR-T cell therapy. (A) Patient 1 with one single focus in left lateral ventricle confirmed by CT plus puncture with pathology (not shown). (B) Patient 3 with one focus in left frontotemporal lobe confirmed by MRI plus puncture with pathology (not shown). Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Clinical outcomes of chimeric antigen receptor T-cell therapy following autologous hematopoietic stem cell transplantation in 38 patients with refractory/relapsed primary or secondary central nervous system lymphoma

Clinical Analysis of Chimeric Antigen Receptor T Cells Immunotherapy in Treatment of One Patient with Relapsed/refractory Primary Central Nervous System Lymphoma

Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma

The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma

CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma

Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children with Central Nervous System Leukemia

Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed/refractory ALL: a case report and literature review

CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain

Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.

Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Central Nervous System Relapse after CAR-T Cell Therapy in B-Cell Malignancies

Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma